| Literature DB >> 29954419 |
Floriane Gallais1, Sylvie J De Martino1,2,3, Erik A Sauleau4, Yves Hansmann1,3,5, Dan Lipsker3,6, Cédric Lenormand1,3,6, Emilie Talagrand-Reboul1, Pierre H Boyer1, Nathalie Boulanger1,2, Benoît Jaulhac1,2,3, Frédéric Schramm7.
Abstract
BACKGROUND: Lyme borreliosis in humans results in a range of clinical manifestations, thought to be partly due to differences in the pathogenicity of the infecting strain. This study compared European human clinical strains of Borreliella afzelii (previously named Borrelia afzelii) using multilocus sequence typing (MLST) to determine their spatial distribution across Europe and to establish whether there are associations between B. afzelii genotypes and specific clinical manifestations of Lyme borreliosis. For this purpose, typing was performed on 63 strains, and data on a further 245 strains were accessed from the literature.Entities:
Keywords: Borrelia; Borreliella; Borreliella afzelii; Lyme borreliosis; Multilocus sequence typing
Mesh:
Year: 2018 PMID: 29954419 PMCID: PMC6027761 DOI: 10.1186/s13071-018-2938-x
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
European countries of origin of the clinical B. afzelii strains included in this study
| Country of origin | Strains typed in this study | Strains typed by Coipan et al. [ | Strains extracted from the MLST database | Total |
|---|---|---|---|---|
| Germany | 1 | 3 | 74 | 78 |
| The Netherlands | – | 76 | – | 76 |
| France | 61 | 1 | 3 | 65 |
| Sloveniaa | – | 1 | 41 | 42 |
| Sweden | – | 14 | – | 14 |
| Austria | – | 12 | 2 | 14 |
| Denmark | – | 6 | – | 6 |
| Hungary | – | 4 | – | 4 |
| Italy | – | 4 | – | 4 |
| Finland | – | 2 | – | 2 |
| Switzerland | 1 | 1 | – | 2 |
| Poland | – | – | 1 | 1 |
| Total | 63 | 124 | 121 | 308 |
aTwo strains mentioned as originating from the former Yugoslavia in the MLST database have been incorporated into the Slovenian strains group
Clinical manifestations associated with the clinical strains included in this study
| Sample | Clinical manifestations | Strains typed in this study | Strains typed by Coipan et al. [ | Strains extracted from the MLST database | Total |
|---|---|---|---|---|---|
| Skin biopsy | EM | 43 | 98 | 49 | 190 |
| MEM | 7 | – | – | 7 | |
| ACAa | 8 | 26 | 7 | 41 | |
| BLa | 3 | – | 5 | 8 | |
| Morphea | – | – | 1 | 1 | |
| Unspecified | – | – | 35 | 35 | |
| CSF | NBa | – | – | 20 | 20 |
| Joints | LAa | 1 | – | 1 | 2 |
| Muscle biopsy | Fasciitisa | 1 | – | – | 1 |
| Blood | Bacteremiaa | – | – | 1 | 1 |
| Unknown | – | – | – | 2 | 2 |
| Disseminated manifestationsa | 20 | 26 | 34 | 80 | |
| Total | 63 | 124 | 121 | 308 | |
Abbreviations: EM, erythema migrans; MEM, multiple erythema migrans; ACA, acrodermatitis chronica atrophicans; NB, neuroborreliosis; BL, borrelial lymphocytoma
aManifestations corresponding to a disseminated form of Lyme borreliosis
Population genetic diversity parameters of B. afzelii strains isolated from clinical samples
| Locus | No. of nucleotides | No. of alleles | No. of SNPs | No. of indels | Hd ± SD | π ± SD |
|---|---|---|---|---|---|---|
|
| 579 | 14 | 11 | 0 | 0.762 ± 0.016 | 0.00199 ± 0.00009 |
|
| 624 | 7 | 6 | 0 | 0.188 ± 0.030 | 0.00033 ± 0.00006 |
|
| 564 | 11 | 9 | 0 | 0.613 ± 0.015 | 0.00134 ± 0.00007 |
|
| 570 | 22 | 16 | 0 | 0.849 ± 0.013 | 0.00297 ± 0.00012 |
|
| 603 | 22 | 14 | 0 | 0.862 ± 0.011 | 0.00449 ± 0.00010 |
|
| 651 | 21 | 15 | 0 | 0.840 ± 0.011 | 0.00281 ± 0.00008 |
|
| 624 | 12 | 9 | 0 | 0.401 ± 0.034 | 0.00088 ± 0.00009 |
|
| 570 | 10 | 8 | 1a | 0.613 ± 0.020 | 0.00135 ± 0.00007 |
| Concatenated sequences | 4785 | 149 | 88 | 1 | 0.984 ± 0.003 | 0.00202 ± 0.00003 |
Abbreviations: SNP, single nucleotide polymorphism; indels, insertions/deletions; Hd, haplotype diversity; π, nucleotide diversity; SD, standard deviation
aAllele 203: insertion of AGATTAAAG between positions 537 and 538 (tandem duplication)
Fig. 1Rooted maximum likelihood tree of B. afzelii based on concatenated sequences of eight MLST housekeeping genes. A total of 149 STs corresponding to 308 B. afzelii isolates grown in vitro from human samples were used in this study, including data previously published by Coipan et al. [15] (n = 126) and data from the MLST database (n = 121) [13, 22]. The total number of strains associated with each ST is indicated in brackets next to the ST. Type strains (T) of B. afzelii (strain VS461) and B. garinii (strain 20047) were also included in the dataset. The bootstrap values obtained on highly supported nodes after 1000 repetitions (with ≥ 70% support) are given below the branches. The grouping of STs into CCs defined by goeBURST analysis at the DLV threshold is indicated by brackets in the case of CC1 to CC12. STs corresponding to singletons are underscored. All other STs belong to the CC0 distributed throughout the tree. The type of infection associated with each strain is indicated by a geometrical shape next to the STs, whereas the geographical origin is indicated by a color (see the legend). Black rectangles give a section of the tree for the sake of better legibility
Fig. 2Overview of the relationships between European B. afzelii STs detected in human samples using goeBURST. CCs were identified at the DLV threshold. The 149 STs clustered into eight major complexes (consisting of three or more STs), five minor complexes (consisting of two STs), and 11 singletons with no connection with any other STs. The circled fraction of CC0 corresponds to CC1’ when CCs were defined at the SLV threshold. Colored lines between STs indicate in descending order of certainty: black lines inferred without tiebreak rules, blue lines inferred using tiebreak rule 1 (number of SLVs), green lines using tiebreak rule 2 (number of DLV), and yellow lines using tiebreak rules 4 or 5 (frequency found on the data set and ST number, respectively). STs connected by gray lines are DLVs. The inferred founders of CCs are outlined in light green and subgroup founders in dark green. Circle size corresponds to MLST sample size. Circle color fractions refer to clinical manifestations associated with STs (see the legend)
Fig. 3Spatial distribution of STs involving the European B. afzelii strains included in this study. Pie charts showing the distribution of the STs involving the 308 B. afzelii strains included in this study in Germany (DE), the Netherlands (NL), France (FR), Slovenia (SI), Austria (AT), Sweden (SE), Denmark (DK), Hungary (HU), Italy (IT), Switzerland (CH) and Poland (PL). The size of each sector is proportional to the total number of strains corresponding to each country (see box). Main STs in the four countries showing the largest numbers of strains (DE, NL, FR and SI) are indicated on the map
Matrix of pairwise FST values of the STs in various European countries. Analyses were not conducted on countries associated with too few clinical strains (i.e. Denmark, Hungary, Italy, Finland, Switzerland and Poland)
| Germany | The Netherlands | France | Slovenia | Sweden | |
|---|---|---|---|---|---|
| FST ( | FST ( | FST ( | FST ( | FST ( | |
| The Netherlands |
| – | – | – | – |
| France |
| 0.02663 | – | – | – |
| Slovenia |
|
| 0.01369 | – | – |
| Sweden | 0.02722 | 0.02356 | -0.00526 | 0.02075 | – |
| Austria | 0.02527 |
| 0.01494 | -0.02581 | 0.02188 |
Values in bold type were significant at a significance threshold of α = 0.0033
Results of the analysis of molecular variance (AMOVA) using strains arranged per country
| df | Percentage variation | Mean F-statistic over loci | ||
|---|---|---|---|---|
| Among countries | 11 | 4.4 | FST = 0.04405 | < 0.00001 |
| Within countries | 296 | 95.6 | – | – |
Abbreviation: df, degrees of freedom
Distribution of STs between patients with localized and disseminated infection. Only STs identified in two or more patients were included
| ST | Total no. of strains | Localized infection | Disseminated infection |
|---|---|---|---|
| 71 | 21 | 9 | 12 |
| 72 | 4 | 3 | 1 |
| 73 | 4 | 1 | 3 |
| 75 | 5 | 3 | 2 |
| 78 | 2 | 2 | 0 |
| 80 | 2 | 1 | 1 |
| 165 | 2 | 2 | 0 |
| 168 | 3 | 2 | 1 |
| 171 | 9 | 5 | 4 |
| 263 | 3 | 2 | 1 |
| 289 | 2 | 2 | 0 |
| 335 | 6 | 4 | 2 |
| 347 | 17 | 10 | 7 |
| 349 | 2 | 2 | 0 |
| 354 | 2 | 1 | 1 |
| 458 | 4 | 1 | 3 |
| 459 | 2 | 1 | 1 |
| 462 | 7 | 4 | 3 |
| 463 | 5 | 2 | 3 |
| 465 | 3 | 2 | 1 |
| 467 | 12 | 12 | 0 |
| 474 | 2 | 1 | 1 |
| 476 | 12 | 10 | 2 |
| 477 | 2 | 1 | 1 |
| 479 | 3 | 2 | 1 |
| 540 | 3 | 1 | 2 |
| 554 | 3 | 3 | 0 |
| 698 | 2 | 2 | 0 |
| 710 | 6 | 4 | 2 |
| 715 | 2 | 2 | 0 |
| 717 | 2 | 2 | 0 |
| 718 | 2 | 2 | 0 |
| 1038 | 2 | 2 | 0 |
| 1046 | 2 | 2 | 0 |
| 1051 | 2 | 2 | 0 |
| 1071 | 11 | 11 | 0 |
| 1073 | 2 | 0 | 2 |
| 1075 | 3 | 2 | 1 |
| 1080 | 5 | 5 | 0 |
| 1084 | 2 | 2 | 0 |
| 1090 | 2 | 2 | 0 |
| 1096 | 2 | 2 | 0 |
| Total | 189 | 131 | 58 |
Distribution of clonal complexes between patients with erythema migrans and neuroborreliosis. Clonal complexes were defined by performing goeBURST analysis at the SLV level. The CCs defined at the SLV threshold were named CC’s. Thirteen major CC’s and seven minor CC’s were identified. The 40 singletons identified were not included
| CC’ (SLV) | EM | NB |
|---|---|---|
| CC0’ a | 42 | 2 |
| CC1’ a | 27 | 12 |
| CC2’ a | 21 | 2 |
| CC3’ a | 11 | 0 |
| CC4’ a | 4 | 0 |
| CC5’ a | 6 | 0 |
| CC6’ a | 7 | 0 |
| CC7’ a | 6 | 0 |
| CC8’ a | 13 | 0 |
| CC9’ a | 7 | 1 |
| CC10’ a | 2 | 0 |
| CC11’ a | 2 | 0 |
| CC12’ a | 3 | 0 |
| CC13’ | 0 | 0 |
| CC14’ | 0 | 0 |
| CC15’ | 3 | 0 |
| CC16’ | 1 | 0 |
| CC17’ | 3 | 0 |
| CC18’ | 1 | 0 |
| CC19’ | 2 | 0 |
aThirteen major CC’s